LifeMD, Inc. - Common Stock (LFMD)
3.8500
+0.1400 (3.77%)
NASDAQ · Last Trade: Nov 22nd, 12:31 AM EST
KeyCorp, through its KeyBanc capital markets division, has issued a significantly more pessimistic forecast for LifeMD (NASDAQ: LFMD) stock, dramatically lowering its price objective to $8.00 from a previous $12.00. This downgrade reflects growing concerns over the telehealth company's financial performance, operational efficiency, and competitive landscape. The immediate
Via MarketMinute · November 20, 2025
Via Benzinga · November 19, 2025
Via Benzinga · November 18, 2025
LifeMD Offers Novo Nordisk’s Ozempic For $499 A Month To Eligible Patientsstocktwits.com
Via Stocktwits · September 30, 2025
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.
Via Chartmill · November 18, 2025
Via Benzinga · November 18, 2025
Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Via Chartmill · November 18, 2025
Via Benzinga · November 18, 2025
As the US market prepares to open on Tuesday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Via Chartmill · November 18, 2025
Via Benzinga · November 18, 2025
Via Benzinga · November 18, 2025
Via Benzinga · November 18, 2025
LifeMD stock plunges after Q3 2025 earnings miss analyst estimates on both revenue and EPS, triggering a major sell-off.
Via Chartmill · November 17, 2025
As the regular session of the US market on Monday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Via Chartmill · November 17, 2025
Here's a look at the details from LifeMD's Q3 earnings report.
Via Benzinga · November 17, 2025
Novo Nordisk offers limited-time $199 pricing on Wegovy and Ozempic, lowers self-pay costs, and prepares for a stronger Wegovy pill rollout.
Via Benzinga · November 17, 2025
Hims & Hers Health (NYSE: HIMS) became a significant after-hours mover on Monday, November 3, 2025, following the release of its third-quarter 2025 financial results and the pivotal announcement of renewed discussions with Novo Nordisk A/S (NYSE: NVO) regarding the potential distribution of Wegovy. While the telehealth platform reported a
Via MarketMinute · November 3, 2025
The convergence of Artificial Intelligence and longevity research is heralding a transformative era, often termed "Longevity AI." This interdisciplinary field leverages advanced computational power to unravel the complexities of human aging, with the ambitious goal of extending not just lifespan, but more crucially, "healthspan"—the period of life spent in good health. At the forefront of [...]
Via TokenRing AI · October 10, 2025
Telehealth companies are getting a fresh infusion of business thanks to obesity drugs. Find out which stocks are benefiting.
Via Investor's Business Daily · September 19, 2025
Discover the stocks with unexpected trading volume in today's session on the US markets.
Via Chartmill · August 7, 2025
Looking for insights into the US markets one hour before the close of the markets on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Via Chartmill · August 6, 2025
Via Benzinga · August 6, 2025